KYMR
Kymera Therapeutics, Inc.Company with tickers: KYMR
CIK
1815442
CUSIP
501575104
Shares Outstanding
82,257,588
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $34,365,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Cost of Revenue | $34,365,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Gross Profit | — | ||||
| Operating Expenses | $118,519,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Research & Development | $98,162,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Operating Income | $-84,154,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Net Income | $-69,234,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| EPS (Basic) | $-0.71 | USD/shares | 2026-03-31 | 10-Q | 2026-04-30 |
| EPS (Diluted) | $-0.71 | USD/shares | 2026-03-31 | 10-Q | 2026-04-30 |